Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer.
American Association of Cancer Research:150 South Independence Mall West, #826:Philadelphia, PA 19106:(215)440-9300, EMAIL: [email protected], INTERNET: http://www.aacr.org, Fax: (215)440-7228
